Warning: count(): Parameter must be an array or an object that implements Countable in /home/customer/www/drugtrialsformoney.com/public_html/wp-content/plugins/redux-framework/redux-core/inc/classes/class-redux-output.php on line 390

Evaluation of the Length of Treatment With PD-1/PD-L1 Inhibitors in Patients With Advanced Solid Tumors

Evaluation of the Length of Treatment With PD-1/PD-L1 Inhibitors in Patients With Advanced Solid Tumors
Conditions:   Advanced Solid Tumors;   NSCLC;   Bladder Cancer;   HNSCC;   Renal Cancer;   Melanoma;   Anal Cancer;   Colorectal Cancer;   Cholangiocarcinoma;   Gastric Cancer;   Hepatocellular Carcinoma
Interventions:   Drug: Continue PD-1/PD-L1 Inhibitors treatment;   Other: Discontinue PD-1/PD-L1-1 inhibitor
Sponsor:   Antoinette J Wozniak
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

December 5, 2019 / by / in
Comments